Total Payments
$114,576
2024 Payments
$658.85
Companies
26
Transactions
609
Medicare Patients
3,979
Medicare Billing
$430,702
Payment Breakdown by Category
Other$97,195 (84.8%)
Travel$9,673 (8.4%)
Food & Beverage$7,646 (6.7%)
Education$61.67 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $97,195 | 39 | 84.8% |
| Travel and Lodging | $9,673 | 30 | 8.4% |
| Food and Beverage | $7,646 | 531 | 6.7% |
| Education | $61.67 | 9 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $101,268 | 226 | $0 (2024) |
| Gilead Sciences, Inc. | $8,657 | 20 | $0 (2018) |
| Janssen Pharmaceuticals, Inc | $1,367 | 139 | $0 (2024) |
| Merck Sharp & Dohme LLC | $433.93 | 32 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $403.24 | 26 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $400.35 | 28 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $306.19 | 19 | $0 (2021) |
| Amarin Pharma Inc. | $298.64 | 27 | $0 (2021) |
| Medtronic Vascular, Inc. | $266.27 | 3 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $232.15 | 14 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $658.85 | 44 | Novartis Pharmaceuticals Corporation ($181.29) |
| 2023 | $468.46 | 29 | Novartis Pharmaceuticals Corporation ($180.04) |
| 2022 | $671.23 | 42 | Novartis Pharmaceuticals Corporation ($230.65) |
| 2021 | $1,041 | 74 | Janssen Pharmaceuticals, Inc ($365.66) |
| 2020 | $712.43 | 56 | Amarin Pharma Inc. ($214.72) |
| 2019 | $8,807 | 49 | Novartis Pharmaceuticals Corporation ($8,373) |
| 2018 | $22,690 | 34 | Novartis Pharmaceuticals Corporation ($18,079) |
| 2017 | $79,528 | 281 | Novartis Pharmaceuticals Corporation ($73,843) |
All Payment Transactions
609 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: Obesity | ||||||
| 11/23/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: Obesity | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $15.95 | General |
| Category: Cardiovascular | ||||||
| 11/07/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $16.21 | General |
| Category: Cardiology | ||||||
| 10/31/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $13.90 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/24/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $13.24 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/14/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $11.25 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/23/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $13.92 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/20/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/16/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $16.09 | General |
| Category: Cardiovascular | ||||||
| 09/11/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $18.77 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/27/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $19.34 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/22/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $17.20 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/20/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $13.81 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/16/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $15.90 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/13/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $20.44 | General |
| Category: Cardiology | ||||||
| 08/06/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $15.21 | General |
| Category: Cardiovascular | ||||||
| 07/30/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $15.06 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 06/25/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 06/20/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $15.37 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/18/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $14.87 | General |
| Category: Heart Failure and Hypertension | ||||||
| 06/17/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $15.65 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/11/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $14.35 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/10/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $13.25 | General |
| Category: Cardiology | ||||||
| 06/04/2024 | Azurity Pharmaceuticals, Inc. | EDARBYCLOR (Drug) | Food and Beverage | In-kind items and services | $14.44 | General |
| Category: CARDIOVASCULAR | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 836 | 1,486 | $365,339 | $86,425 |
| 2022 | 12 | 1,016 | 1,787 | $464,097 | $112,414 |
| 2021 | 12 | 1,076 | 1,827 | $508,353 | $121,118 |
| 2020 | 13 | 1,051 | 1,715 | $482,558 | $110,746 |
Total Patients
3,979
Total Services
6,815
Medicare Billing
$430,702
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 210 | 482 | $118,090 | $39,477 | 33.4% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 52 | 52 | $101,400 | $13,740 | 13.6% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 55 | 56 | $32,200 | $7,277 | 22.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 222 | 532 | $31,920 | $5,108 | 16.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 60 | 75 | $12,750 | $5,020 | 39.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 34 | 37 | $12,395 | $4,662 | 37.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 35 | 35 | $14,875 | $4,415 | 29.7% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 50 | 98 | $20,580 | $2,728 | 13.3% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 28 | 28 | $4,900 | $1,302 | 26.6% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 24 | 24 | $11,079 | $1,096 | 9.9% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 54 | 54 | $2,160 | $932.04 | 43.2% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 12 | 13 | $2,990 | $666.55 | 22.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 216 | 499 | $122,255 | $42,292 | 34.6% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2022 | 70 | 70 | $136,500 | $19,332 | 14.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 91 | 91 | $52,325 | $13,244 | 25.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 92 | 131 | $22,270 | $8,737 | 39.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 52 | 52 | $22,100 | $8,027 | 36.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 229 | 608 | $36,480 | $5,987 | 16.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 41 | 46 | $15,410 | $5,764 | 37.4% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2022 | 65 | 129 | $27,090 | $3,544 | 13.1% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2022 | 35 | 35 | $16,157 | $1,698 | 10.5% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2022 | 36 | 36 | $6,300 | $1,692 | 26.9% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 71 | 71 | $2,840 | $1,226 | 43.2% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2022 | 18 | 19 | $4,370 | $871.95 | 20.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 197 | 448 | $109,760 | $37,767 | 34.4% |
About Dr. David Utlak, M.D
Dr. David Utlak, M.D is a Cardiovascular Disease healthcare provider based in Canton, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/19/2005. The National Provider Identifier (NPI) number assigned to this provider is 1548269756.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Utlak, M.D has received a total of $114,576 in payments from pharmaceutical and medical device companies, with $658.85 received in 2024. These payments were reported across 609 transactions from 26 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($97,195).
As a Medicare-enrolled provider, Utlak has provided services to 3,979 Medicare beneficiaries, totaling 6,815 services with total Medicare billing of $430,702. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Canton, OH
- Active Since 07/19/2005
- Last Updated 08/29/2023
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1548269756
Products in Payments
- ENTRESTO (Drug) $100,958
- Ranexa (Drug) $8,588
- XARELTO (Drug) $1,367
- VERQUVO (Drug) $433.93
- ELIQUIS (Drug) $330.86
- JARDIANCE (Drug) $320.23
- LEQVIO (Drug) $310.98
- Vascepa (Drug) $298.64
- BRILINTA (Drug) $216.23
- Micra (Device) $194.37
- MULTAQ (Drug) $170.59
- FUROSCIX (Drug) $136.89
- Edarbi (Drug) $114.13
- Corlanor (Drug) $102.95
- LifeVest (Device) $99.59
- EMBLEM (Device) $87.92
- PRADAXA (Drug) $83.01
- Repatha (Biological) $77.08
- ATRIAL FIBRILLATION - DISEASE (Drug) $74.29
- Azure (Device) $71.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Canton
Steven Hirsch, M.d, M.D
Cardiovascular Disease — Payments: $81,287
Cardiovascular Disease $81,287
Jennifer Cummings, M.d, M.D
Cardiovascular Disease — Payments: $69,593
Cardiovascular Disease $69,593
Dr. Anjan Deka, M.d, M.D
Cardiovascular Disease — Payments: $20,639
Cardiovascular Disease $20,639
Dr. Bharat Surani, D.o, D.O
Cardiovascular Disease — Payments: $15,146
Cardiovascular Disease $15,146
Dr. Sajeevani Kim, Md, Phd, MD, PHD
Cardiovascular Disease — Payments: $13,204
Cardiovascular Disease $13,204
Dr. Aashish Desai, M.d, M.D
Cardiovascular Disease — Payments: $10,973
Cardiovascular Disease $10,973